Skip to main content
. 2021 Apr 1;13(4):479. doi: 10.3390/pharmaceutics13040479

Table 1.

Graphical representation of tested formulations and their composition. The siRNA concentration was 30 nM for all the formulations

graphic file with name pharmaceutics-13-00479-i001.jpg graphic file with name pharmaceutics-13-00479-i002.jpg graphic file with name pharmaceutics-13-00479-i003.jpg graphic file with name pharmaceutics-13-00479-i004.jpg graphic file with name pharmaceutics-13-00479-i005.jpg graphic file with name pharmaceutics-13-00479-i006.jpg graphic file with name pharmaceutics-13-00479-i007.jpg
DOPC (mg/mL) 2 2 2 2 1.8 1.8
Poloxamer (mg/mL) - 50 - 50 - 50
DMAPAP (mg/mL) - - - - 0.2 0.2
PEI (mg/mL) - - 0.03 0.03 - -